metastatic castration resistant prostate cancer
Conditions
Interventions
The study subjects are mCRPC patients who have undergone LuPSMA therapy. After admission to a dedicated treatment room, patients receive the prescribed dose of LuPSMA on the day of administration and
s radioisotope (RI) laboratory to capture images of the lesion using gamma rays emitted by LuPSMA. This will be performed after the first six treatments to assess whether it is useful for assessing tr
Sponsors
Gunma University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: (1) Adult men aged 20 years or older (2) Patients pathologically diagnosed with prostate cancer (3) Patients with mCRPC undergoing LuPSMA therapy at our hospital (4) Patients who provide written informed consent to participate in this study
Exclusion criteria
Exclusion criteria: (1) Patients who do not consent to this study or who refuse to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| radiographic progression free survival; rPFS | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival from the start of LuPSMA treatment Response assessment after completion of LuPSMA treatment (CR, PR, SD, PD) Side effects assessment Tumor marker changes | — |
Countries
Japan
Contacts
Public ContactYoshiyuki Miyazawa
Gunma University Hospital Department of Urology
Outcome results
None listed